Biotech Stock Collapses After Failed Drug Study

Short sellers have been flocking to VBLT in recent weeks

Managing Editor
Mar 8, 2018 at 9:59 AM
facebook twitter linkedin

Vascular Biogenics Ltd (NASDAQ:VBLT) is the worst stock on the Nasdaq today, down 65% to trade at $2.38 -- and just off a new record low of $2.30 -- after the biotech's brain cancer drug failed to meet its late-stage study goals. However, the company said it believes VB-111 "may still hold promise for other indications we currently or may study in the future."

Prior to today's freefall, VBLT stock had tacked on 19% year-over-year, and had found support at its 200-day moving average, after pulling back from a two-year high of $9.05 on Nov. 16. Now, however, the security is on track for its worst single-day performance of all time. 

Although the stock is currently short-sale restricted, plenty of short sellers are likely cheering today's collapse. Short interest increased by nearly 60% during the last two reporting periods, and now represents 6.7% of VBLT's total available float.

Analysts could re-think their bullish positions on the tanking drug name. The three brokerage firms tracking VBLT rate it a "strong buy," while the stock's average 12-month price-target of $14.75 represents a 520% premium to its current perch. Should VBLT continue to languish, it could prompt downgrades and/or price-target cuts. 


Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 



Special Offers from Schaeffer's Trading Partners